Generic Drug Salsalate Continues to Show Promise

Results from a three-month trial show that those who took salsalate demonstrated significantly improved blood glucose levels.

| Apr 10, 2010

We continue to monitor the progress of studies to determine the effectiveness of salsalate, a generic aspirin-like drug, to reduce inflammation and lower blood glucose in people with type 2 diabetes.  As previously reported here in October 2008 and January 2009, researchers from the Joslin Diabetes Center at Harvard University are conducting clinical trials to determine if this well known and proven drug for joint pain can be added to the list of diabetes drugs.  Recently, results from a three-month trial were announced online in the Annals of Internal Medicine, showing that those who took salsalate demonstrated significantly improved blood glucose levels.

This small trial, involving 108 patients, revealed that hemoglobin A1c levels dropped by 0.5% among those taking salsalate, a result that is on par with some recently released diabetes drugs.  Other measures related to glucose were also improved.  "These results are exciting," says Allison Goldfine, MD, Joslin's Director of Clinical Research, an Associate Professor at Harvard Medical School, and the first author of the article.  "They indicate that salsalate may provide an effective, safe, and inexpensive new avenue for diabetes treatment.  However, these findings are preliminary, and we do not recommend patients use this medication for their diabetes treatment until further studies are completed."

Research on the use of salsalate for diabetes was triggered by the investigations of Steven Shoelson, MD, PhD, head of the Joslin Diabetes Center's Section on Pathophysiology and Molecular Pharmacology as well as Professor at Harvard Medical School.  In the 1990s, he discovered a report by a 19th century German doctor, which suggested that the anti-inflammatory agent sodium salicylate could be a diabetes treatment.  Sodium salicylate, similar to aspirin, is a stomach irritant at high doses.  The less irritating salsalate was considered as a treatment at that time, but it never caught on, "probably because people didn't know the difference between type 1 and type 2 diabetes," says Shoelson.  Salsalate has no impact on type 1 diabetes. However, "modern-day thinking about inflammation being a mediator in [type 2] diabetes," he says, prompted his animal model research that found promising results from salsalate. 

"It may turn out that this is an inexpensive and somewhat effective treatment for diabetes, but there are a lot of 'if's' that have to be answered along the way," says Robert Vigersky, president of the Endocrine Society and director of the Diabetes Institute at Walter Reed Army Medical Center.  "It clearly is not as potent as Avandia and Actos," he says, "but it does add another drug that we can use in various combinations" for treatment. Dr. Vigersky is not involved in the current trial.

Pharmaceutical companies are interested in anti-inflammatories for diabetes treatments, but are not pursuing salsalate because of its generic status and lack of profit potential.  "So we went for funding to the federal government, which has been interested in a safe, effective and inexpensive new drug for diabetes," states Dr. Shoelson.  Salsalate studies, which are funded by the National Institute of Diabetes and Digestive and Kidney Diseases along with Joslin Center, are moving forward in a larger Phase 3 clinical trial.  It is possible that salsalate could be used as an add-on treatment with other drugs, especially to reduce microvascular and macrovascular complications related to diabetes.

* * *

Sources:

Joslin.org news

USNews.com health report

Click Here To View Or Post Comments

Categories: A1c Test, Blood Glucose, Blood Sugar, Complementary Therapies, Diabetes, Diabetes, Type 1 Issues, Type 2 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.